Compare BFH & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFH | LIVN |
|---|---|---|
| Founded | 1996 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.3B |
| IPO Year | 2000 | 2015 |
| Metric | BFH | LIVN |
|---|---|---|
| Price | $101.82 | $76.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | ★ $115.00 | $90.55 |
| AVG Volume (30 Days) | 518.5K | ★ 604.7K |
| Earning Date | 10-22-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 98.36 | N/A |
| EPS | ★ 7.72 | 2.33 |
| Revenue | ★ $4,521,400,000.00 | N/A |
| Revenue This Year | $4.40 | $9.65 |
| Revenue Next Year | $3.51 | $7.11 |
| P/E Ratio | ★ $13.14 | $33.12 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $57.11 | $48.82 |
| 52 Week High | $114.53 | $85.76 |
| Indicator | BFH | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 51.51 |
| Support Level | $93.39 | $77.28 |
| Resistance Level | $105.20 | $82.39 |
| Average True Range (ATR) | 3.05 | 1.89 |
| MACD | 0.18 | 0.23 |
| Stochastic Oscillator | 74.38 | 100.00 |
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business, which partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.